logo-loader
viewPolarean Imaging PLC

Polarean Imaging signs deal with University of British Colombia

CEO Richard Hullihen said: “UBC has a long history and pioneering reputation in the field of medical imaging research and I look forward to providing further updates regarding our collaboration with UBC as appropriate.”

1550218265_shutterstock_703970935.jpg
The company is a specialist in medical imaging

Polarean Imaging Plc (LON:POLX), the medical imaging technology company, said the University of British Columbia (UBC) is acquiring one of the company’s polarizer systems.

No financial details were mentioned, but the Polarean release said UBC has received support from the Canada Foundation for Innovation.

The company’s chief executive, Richard Hullihen, said: "We are excited to welcome Doctors Sin and Leipsic and the staff of UBC to our expanding base of collaborative researchers and look forward to assisting them in achieving the goals of their research programme.

“UBC has a long history and pioneering reputation in the field of medical imaging research and I look forward to providing further updates regarding our collaboration with UBC as appropriate.”

Quick facts: Polarean Imaging PLC

Price: 26 GBX

AIM:POLX
Market: AIM
Market Cap: £42.08 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Polarean Imaging welcomes new strategic investor as it raises £8.4mln in new...

Polarean Imaging PLC's (LON:POLX) Richard Hullihen speaks to Proactive London's Andrew Scott after conditionally raising £8.4mln (US$10.7mln) before expenses. He says the extra cash will help to strengthen its balance sheet while it prepares for the new drug application (NDA) for its...

on 18/3/20

2 min read